Vera Therapeutics to Host Business Update Call

Rhea-AI Summary

Vera Therapeutics, Inc. (Nasdaq: VERA), a late-stage biotechnology company, will host a business update call on March 24, 2022, at 8:00 a.m. ET. The company is focused on developing transformative treatments for serious immunological diseases. Investors can participate via a toll-free number or an international line, and a webcast will be available 15 minutes prior to the call. Vera's lead candidate, atacicept, targets autoimmune diseases such as IgA nephropathy and lupus nephritis. For details, visit www.veratx.com.

BRISBANE, Calif., March 17, 2022 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, will host a business update call at 8:00 a.m. ET on March 24, 2022.

Title:	Vera Therapeutics Business Update Call
Date:	Thursday, March 24, 2022
Time:	8:00 a.m. ET
Conference Call Details:	Toll-Free: 1-877-423-9813 International: 1-201-689-8573 Conference ID: 13727899
Webcast:	Webcast Link- Click Here

The webcast should be accessed 15 minutes prior to the conference call start time. A replay of the webcast will be available following the conclusion of the live broadcast and will be accessible on Vera Therapeutics’ website.

About Vera Therapeutics
Vera Therapeutics is a late-stage biotechnology company focused on developing treatments for serious immunological diseases. Vera’s mission is to advance treatments that target the source of immunologic diseases in order to change the standard of care for patients. Vera’s lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B lymphocyte stimulator (BLyS) and a proliferation inducing ligand (APRIL), which stimulate B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases, including IgA nephropathy (IgAN), also known as Berger’s disease and lupus nephritis. In addition, Vera is evaluating additional diseases where the reduction of autoantibodies by atacicept may prove medically useful. Vera is also developing MAU868, a monoclonal antibody designed to neutralize infection with BK Virus, a polyomavirus that can have devastating consequences in certain settings such as kidney transplant. For more information, please visit www.veratx.com.

For more information, please contact:

Investor Contact:
Joyce Allaire
LifeSci Advisors
212-915-2569
jallaire@lifesciadvisors.com

Media Contact:
Kathy Vincent
Greig Communications, Inc.
kathy@greigcommunications.com

FAQ

What is the date and time of Vera Therapeutics' business update call?

The business update call is scheduled for March 24, 2022, at 8:00 a.m. ET.

How can I access the Vera Therapeutics business update call?

You can access the call via a toll-free number at 1-877-423-9813 or the international number 1-201-689-8573.

What is the purpose of the Vera Therapeutics business update call?

The call aims to provide updates on the company's developments in treatments for serious immunological diseases.

When will a replay of the Vera Therapeutics webcast be available?

A replay of the webcast will be available after the live broadcast on Vera Therapeutics' website.

What is atacicept and its significance to Vera Therapeutics?

Atacicept is Vera's lead product candidate targeting autoimmune diseases, aiming to change the standard of care.